Zai Lab (ZLAB) Receivables (2018 - 2026)
Zai Lab (ZLAB) posted Receivables of $54.1 million for Q1 2026, down 49.05% sequentially from $106.1 million in Q4 2025, and down 29.37% YoY from $76.6 million in Q1 2025.
Analysis
Zai Lab (ZLAB) Receivables (2018 - 2026) Analysis & Trends
Zai Lab has reported Receivables for 9 years, with the latest figure at $54.1 million in Q1 2026.
- Quarterly Receivables fell 29.37% year-over-year to $54.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.1 million (down 29.37% YoY) and the FY2025 annual result came in at $106.1 million, up 24.58% from the prior year.
- Receivables fell to $54.1 million in Q1 2026 per ZLAB's latest filing, from $106.1 million in the prior quarter.
- Over five years, Receivables peaked at $106.1 million in Q4 2025 and troughed at $7.8 million in Q4 2023.
- A 5-year average of $55.5 million and a median of $50.0 million in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2023 and 2024: Receivables sank 80.48% in 2023, then jumped 992.03% in 2024.
- Over 5 years, Receivables stood at $40.0 million in 2022, then tumbled by 80.48% to $7.8 million in 2023, then surged by 992.03% to $85.2 million in 2024, then advanced by 24.58% to $106.1 million in 2025, then plunged by 49.05% to $54.1 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $54.1 million, $106.1 million, and $85.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Zai Lab | 2.94 Bn | 2.23 Bn | 58.15 Mn | 69.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 69.60 Mn |
| Mar 31, 2026 | 54.07 Mn |
| Dec 31, 2025 | 106.12 Mn |
| Sep 30, 2025 | 85.38 Mn |
| Jun 30, 2025 | 88.50 Mn |
| Mar 31, 2025 | 76.56 Mn |
| Dec 31, 2024 | 16.70 Mn |
| Sep 30, 2024 | 49.97 Mn |
| Jun 30, 2024 | 69.64 Mn |
| Mar 31, 2024 | 60.42 Mn |
| Dec 31, 2023 | 7.80 Mn |
| Sep 30, 2023 | 41.60 Mn |
| Jun 30, 2023 | 47.28 Mn |
| Mar 31, 2023 | 43.35 Mn |
| Dec 31, 2022 | 39.96 Mn |
| Sep 30, 2022 | 27.74 Mn |
| Jun 30, 2022 | 27.05 Mn |
| Mar 31, 2022 | 33.39 Mn |
| Dec 31, 2021 | 47.47 Mn |
| Sep 30, 2021 | 21.02 Mn |